Effect of Dapagliflozin on Blood Pressure Variability in Prediabetes and Prehypertension
Status:
Completed
Trial end date:
2018-06-29
Target enrollment:
Participant gender:
Summary
Prediabetes is defined as an intermediate metabolic state that leads to the development of
type 2 diabetes mellitus (DM2) and the prehypertension is a category assigned to identify
patients who are at risk of developing hypertension (AH), in both pathologies the
abnormalities in the variation of blood pressure (BP) has been related to organ damage, its
evaluation is performed by ambulatory blood pressure monitoring (ABPM).
Dapagliflozin is a selective and reversible inhibitor of the sodium-glucose co-transporter
type 2 (SGLT-2), which reduces renal reabsorption of glucose and promotes the excretion of
glucose through the urine, in the way that glucose blood. Another reported effects is the
decrease on BP, so it would be interesting to evaluate this effects in patients with
prediabetes and prehypertension, as a potential therapy to treat disorders and to prevent
progression to DM2 and Hypertension, respectively.
The aim of this study is to evaluate the effect of Dapagliflozin on variability of blood
pressure in patients with prediabetes and prehypertension without pharmacological treatment.
The investigators hypothesis is that the administration of dapagliflozin decreases
variability of blood pressure in patients with prediabetes and prehypertension without
pharmacological treatment.